Symbols / ROIV Stock $28.70 +1.59% Roivant Sciences Ltd.

Healthcare • Biotechnology • United Kingdom • NMS
ROIV (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Matthew Gline
Exch · Country NMS · United Kingdom
Market Cap 20.64B
Enterprise Value 17.22B
Income -299.77M
Sales 8.26M
FCF (ttm) -1.09B
Book/sh 6.02
Cash/sh 5.97
Employees 721
Insider 10d —
IPO Dec 08, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -18.41
PEG —
P/S 2,499.16
P/B 4.77
P/C —
EV/EBITDA -13.49
EV/Sales 2,085.20
Quick Ratio 18.00
Current Ratio 18.37
Debt/Eq 2.03
LT Debt/Eq —
EPS (ttm) -0.54
EPS next Y -1.56
EPS Growth —
Revenue Growth -66.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-10
Earnings (prior) 2026-05-20
ROA -14.35%
ROE -7.59%
ROIC —
Gross Margin 0.00%
Oper. Margin -146.75%
Profit Margin 0.00%
Shs Outstand 719.27M
Shs Float 545.51M
Insider Own 23.39%
Instit Own 75.89%
Short Float 5.02%
Short Ratio 5.27
Short Interest 27.38M
52W High 32.79
vs 52W High -12.48%
52W Low 10.71
vs 52W Low 168.10%
Beta 1.14
Impl. Vol. 71.68%
Rel Volume 0.58
Avg Volume 5.87M
Volume 3.41M
Target (mean) $39.04
Tgt Median $40.00
Tgt Low $31.50
Tgt High $45.00
# Analysts 12
Recom Strong_buy
Prev Close $28.25
Price $28.70
Change 1.59%
About

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$39.04
Mean price target
2. Current target
$28.70
Latest analyst target
3. DCF / Fair value
$-27.29
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.70
Low
$31.50
High
$45.00
Mean
$39.04

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-26 main Guggenheim Buy → Buy $36
2026-05-21 main Citigroup Buy → Buy $42
2026-05-21 main TD Cowen Buy → Buy $41
2026-05-21 reit HC Wainwright & Co. Buy → Buy $34
2026-04-16 main Piper Sandler Overweight → Overweight $40
2026-03-04 main HC Wainwright & Co. Buy → Buy $34
2026-02-10 main Citigroup Buy → Buy $35
2026-02-10 main HC Wainwright & Co. Buy → Buy $33
2026-02-09 main Guggenheim Buy → Buy $30
2025-12-15 main Leerink Partners Outperform → Outperform $32
2025-12-15 main Goldman Sachs Buy → Buy $33
2025-12-12 main HC Wainwright & Co. Buy → Buy $26
2025-11-11 main Citigroup Buy → Buy $26
2025-10-29 main Citigroup Buy → Buy $25
2025-09-18 main Goldman Sachs Buy → Buy $24
2025-09-18 main Jefferies Buy → Buy $20
2025-09-18 main JP Morgan Overweight → Overweight $20
2025-09-18 main Guggenheim Buy → Buy $21
2025-09-18 main Leerink Partners Outperform → Outperform $22
2025-09-18 main B of A Securities Neutral → Neutral $17
News
RSS: Latest ROIV news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-22 VENKER ERIC President — 200,000 $3.85 $770,000
2026-05-22 VENKER ERIC President — 200,000 $30.27 $6,054,000
2026-04-20 PULIK RICHARD Chief Financial Officer — 60,644 $0.00 $0
2026-04-20 HUMES JENNIFER Officer — 29,173 $0.00 $0
2026-04-20 VENKER ERIC Officer — 200,000 $3.85 $770,000
2026-04-20 VENKER ERIC Officer — 200,000 $29.59 $5,918,000
2026-04-17 MOMTAZEE JAMES C Director — 469 $0.00 $0
2026-04-17 OREN ILAN Director — 896 $0.00 $0
2026-04-17 EPPERLY MELISSA B Director — 670 $0.00 $0
2026-04-16 GLINE MATTHEW Chief Executive Officer — 289,774 $29.16 $8,449,810
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2026-03-31 2025-03-31 2024-03-31 2023-03-31
Total Revenue
8.26
-71.57%
29.05
-11.19%
32.71
+3.75%
31.53
Operating Revenue
8.26
-71.57%
29.05
-11.19%
32.71
+3.75%
31.53
Cost Of Revenue
1.28
+41.05%
0.91
-43.03%
1.60
-47.30%
3.03
Reconciled Cost Of Revenue
1.28
+41.05%
0.91
-43.03%
1.60
-47.30%
3.03
Gross Profit
6.97
-75.21%
28.14
-9.55%
31.11
+9.19%
28.50
Operating Expense
1,292.28
+13.18%
1,141.82
+33.38%
856.04
+2.21%
837.51
Research And Development
681.81
+23.87%
550.41
+25.12%
439.91
-3.12%
454.06
Selling General And Administration
610.47
+3.22%
591.41
+42.12%
416.13
+8.52%
383.45
General And Administrative Expense
610.47
+3.22%
591.41
+42.12%
416.13
+8.52%
383.45
Other Gand A
610.47
+3.22%
591.41
+42.12%
416.13
+8.52%
383.45
Total Expenses
1,293.56
+13.20%
1,142.73
+33.24%
857.64
+2.03%
840.54
Operating Income
-1,285.30
-15.41%
-1,113.68
-35.00%
-824.93
-1.97%
-809.01
Total Operating Income As Reported
-515.07
+48.66%
-1,003.29
-122.31%
4,497.03
+595.94%
-906.76
EBITDA
-1,281.95
-16.58%
-1,099.61
-36.96%
-802.89
-1.61%
-790.16
Normalized EBITDA
-2,168.26
-70.96%
-1,268.29
+79.24%
-6,109.65
-771.73%
-700.87
Reconciled Depreciation
3.35
-76.21%
14.07
-36.15%
22.04
+16.86%
18.86
EBIT
-1,285.30
-15.41%
-1,113.68
-35.00%
-824.93
-1.97%
-809.01
Total Unusual Items
886.31
+425.43%
168.68
-96.82%
5,306.76
+6043.42%
-89.29
Total Unusual Items Excluding Goodwill
886.31
+425.43%
168.68
-96.82%
5,306.76
+6043.42%
-89.29
Special Income Charges
781.26
+588.37%
113.50
-97.88%
5,354.73
+7920.21%
-68.47
Other Special Charges
-770.24
—
26.45
-72.94%
97.75
Restructuring And Mergern Acquisition
—
—
26.45
-72.94%
97.75
Net Income
-299.77
-74.30%
-171.98
-103.95%
4,348.93
+531.00%
-1,009.03
Pretax Income
-264.58
+61.18%
-681.59
-114.92%
4,567.86
+616.15%
-884.99
Net Non Operating Interest Income Expense
178.11
-31.07%
258.38
+76.46%
146.43
+354.96%
32.18
Interest Expense Non Operating
—
—
34.78
+24.35%
27.97
Net Interest Income
178.11
-31.07%
258.38
+76.46%
146.43
+354.96%
32.18
Interest Expense
—
—
34.78
+24.35%
27.97
Interest Income Non Operating
178.11
-31.07%
258.38
+76.46%
146.43
+354.96%
32.18
Interest Income
178.11
-31.07%
258.38
+76.46%
146.43
+354.96%
32.18
Other Income Expense
842.62
+385.05%
173.72
-96.69%
5,246.36
+4950.55%
-108.16
Other Non Operating Income Expenses
-43.69
-967.77%
5.04
+108.34%
-60.40
-220.05%
-18.87
Gain On Sale Of Security
105.05
+90.35%
55.19
+215.04%
-47.97
-130.47%
-20.82
Gain On Sale Of Business
11.03
-90.28%
113.50
-97.89%
5,381.18
+18280.86%
29.28
Tax Provision
133.33
+176.77%
48.17
+124.03%
21.50
+426.78%
4.08
Tax Rate For Calcs
0.00
+60.00%
0.00
+5211.24%
0.00
-97.52%
0.00
Tax Effect Of Unusual Items
354.52
+740.70%
42.17
+68.81%
24.98
+247.25%
-16.96
Net Income Including Noncontrolling Interests
-397.91
-11.54%
-356.73
-108.43%
4,231.21
+479.32%
-1,115.46
Net Income From Continuing Operation Net Minority Interest
-299.77
+45.00%
-545.01
-111.69%
4,664.07
+695.94%
-782.64
Net Income From Continuing And Discontinued Operation
-299.77
-74.30%
-171.98
-103.95%
4,348.93
+531.00%
-1,009.03
Net Income Continuous Operations
-397.91
+45.47%
-729.76
-116.05%
4,546.35
+611.36%
-889.07
Net Income Discontinuous Operations
0.00
-100.00%
373.03
+218.37%
-315.15
-39.20%
-226.39
Minority Interests
98.14
-46.88%
184.75
+56.94%
117.72
+10.60%
106.43
Normalized Income
-831.56
-23.83%
-671.52
-8.71%
-617.70
+13.04%
-710.32
Net Income Common Stockholders
-299.77
-74.30%
-171.98
-103.95%
4,348.93
+531.00%
-1,009.03
Diluted EPS
-0.54
-125.00%
-0.24
-104.59%
5.23
+468.31%
-1.42
Basic EPS
-0.43
-79.17%
-0.24
-104.32%
5.55
+490.85%
-1.42
Basic Average Shares
693.86
-4.35%
725.40
-7.39%
783.25
+9.88%
712.79
Diluted Average Shares
693.86
-4.35%
725.40
-12.71%
831.05
+16.59%
712.79
Diluted NI Availto Com Stockholders
-299.77
-74.30%
-171.98
-103.95%
4,348.93
+531.00%
-1,009.03
Earnings From Equity Interest
—
—
—
—
Line Item Trend 2026-03-31 2025-03-31 2024-03-31 2023-03-31
Total Assets
5,708.69
+5.00%
5,436.94
-24.72%
7,222.48
+202.25%
2,389.60
Current Assets
5,167.38
+3.35%
5,000.06
-25.73%
6,731.83
+274.28%
1,798.59
Cash Cash Equivalents And Short Term Investments
4,291.83
-12.18%
4,886.89
-24.76%
6,494.95
+287.34%
1,676.81
Cash And Cash Equivalents
1,419.23
-47.73%
2,715.41
-58.19%
6,494.95
+287.34%
1,676.81
Cash Equivalents
1,374.71
-47.56%
2,621.46
-58.47%
6,312.29
—
Cash Financial
44.53
-52.61%
93.95
-48.56%
182.66
—
Other Short Term Investments
2,872.60
+32.29%
2,171.48
0.00
—
Receivables
770.24
0.00
-100.00%
82.81
+119.99%
37.64
Accounts Receivable
—
—
53.55
+76.26%
30.38
Other Receivables
770.24
—
—
—
Taxes Receivable
—
—
1.83
-22.45%
2.36
Accrued Interest Receivable
—
—
27.44
+458.99%
4.91
Inventory
—
—
35.25
+1176.75%
2.76
Prepaid Assets
—
—
55.10
-9.42%
60.83
Restricted Cash
—
—
5.37
+7.10%
5.01
Assets Held For Sale Current
—
0.00
-100.00%
156.27
—
Other Current Assets
105.32
-6.94%
113.17
+40.40%
80.61
+418.99%
15.53
Total Non Current Assets
541.30
+23.90%
436.88
-10.96%
490.65
-16.98%
591.02
Net PPE
92.40
-8.58%
101.08
+70.38%
59.32
-35.75%
92.34
Gross PPE
92.40
-8.58%
101.08
+70.38%
59.32
-35.75%
92.34
Other Properties
92.40
-8.58%
101.08
+70.38%
59.32
-35.75%
92.34
Goodwill And Other Intangible Assets
—
—
137.84
-4.86%
144.88
Investments And Advances
407.99
+34.68%
302.94
+22.27%
247.75
-18.59%
304.32
Other Investments
407.99
+34.68%
302.94
+22.27%
247.75
-18.59%
304.32
Other Non Current Assets
40.92
+24.52%
32.86
-82.10%
183.58
+271.00%
49.48
Total Liabilities Net Minority Interest
416.27
+66.68%
249.74
-67.73%
773.95
-1.03%
782.02
Current Liabilities
281.24
+88.24%
149.41
-43.99%
266.76
-2.09%
272.45
Payables And Accrued Expenses
182.19
+115.68%
84.47
-9.49%
93.33
-29.69%
132.75
Payables
63.69
+164.20%
24.11
+1.28%
23.80
-37.97%
38.37
Accounts Payable
18.00
-24.01%
23.69
+68.87%
14.03
-62.92%
37.83
Current Accrued Expenses
118.50
+96.30%
60.37
-13.18%
69.53
-26.33%
94.37
Pensionand Other Post Retirement Benefit Plans Current
87.33
+61.93%
53.93
+8.09%
49.89
-9.60%
55.19
Total Tax Payable
45.69
+10882.93%
0.42
-95.74%
9.77
+1703.14%
0.54
Income Tax Payable
45.69
+10882.93%
0.42
-95.74%
9.77
+1703.14%
0.54
Current Debt And Capital Lease Obligation
11.15
+13.26%
9.84
+9.77%
8.97
-82.89%
52.41
Current Debt
—
—
12.00
-70.53%
40.72
Other Current Borrowings
—
—
12.00
-70.53%
40.72
Current Capital Lease Obligation
11.15
+13.26%
9.84
+9.77%
8.97
-23.32%
11.69
Current Deferred Liabilities
—
1.17
-71.98%
4.17
-66.51%
12.44
Current Deferred Revenue
—
1.17
-71.98%
4.17
-66.51%
12.44
Other Current Liabilities
0.58
-50.09%
1.17
-98.94%
110.41
+5182.54%
2.09
Total Non Current Liabilities Net Minority Interest
135.03
+34.59%
100.33
-80.22%
507.19
-0.47%
509.57
Liabilities Heldfor Sale Non Current
—
0.00
-100.00%
433.94
—
Long Term Debt And Capital Lease Obligation
96.29
+6.60%
90.33
+100.64%
45.02
-89.51%
428.99
Long Term Debt
—
—
430.59
+14.67%
375.51
Long Term Capital Lease Obligation
96.29
+6.60%
90.33
+100.64%
45.02
-15.81%
53.48
Tradeand Other Payables Non Current
38.67
0.00
—
—
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Revenue
—
—
—
—
Other Non Current Liabilities
0.07
-99.30%
10.00
-64.57%
28.23
-64.97%
80.58
Stockholders Equity
4,527.37
-3.42%
4,687.60
-21.46%
5,968.58
+415.53%
1,157.77
Common Stock Equity
4,527.37
-3.42%
4,687.60
-21.46%
5,968.58
+415.53%
1,157.77
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
720.35
+3.51%
695.94
-13.73%
806.68
+6.12%
760.14
Ordinary Shares Number
720.35
+3.51%
695.94
-13.73%
806.68
+6.12%
760.14
Additional Paid In Capital
5,024.83
+10.14%
4,562.11
-15.46%
5,396.49
+9.39%
4,933.14
Retained Earnings
-501.81
-532.37%
116.06
-79.86%
576.17
+115.27%
-3,772.75
Gains Losses Not Affecting Retained Earnings
4.36
-53.82%
9.44
+331.15%
-4.08
-56.02%
-2.62
Minority Interest
765.04
+53.13%
499.59
+4.09%
479.95
+6.70%
449.82
Other Equity Adjustments
4.36
-53.82%
9.44
+331.15%
-4.08
-56.02%
-2.62
Total Equity Gross Minority Interest
5,292.41
+2.03%
5,187.20
-19.56%
6,448.53
+301.13%
1,607.59
Total Capitalization
4,527.37
-3.42%
4,687.60
-21.46%
5,968.58
+289.27%
1,533.28
Working Capital
4,886.14
+0.73%
4,850.65
-24.97%
6,465.07
+323.62%
1,526.14
Invested Capital
4,527.37
-3.42%
4,687.60
-21.46%
5,968.58
+279.20%
1,574.00
Total Debt
107.44
+7.26%
100.17
+85.55%
53.99
-88.79%
481.40
Capital Lease Obligations
107.44
+7.26%
100.17
+85.55%
53.99
-17.16%
65.17
Net Tangible Assets
4,527.37
-3.42%
4,687.60
-21.46%
5,968.58
+489.27%
1,012.88
Tangible Book Value
4,527.37
-3.42%
4,687.60
-21.46%
5,968.58
+489.27%
1,012.88
Current Provisions
—
—
23.28
+32.49%
17.57
Line Item Trend 2026-03-31 2025-03-31 2024-03-31 2023-03-31
Operating Cash Flow
-750.35
+10.61%
-839.45
-9.69%
-765.27
+9.26%
-843.39
Cash Flow From Continuing Operating Activities
-750.35
+10.61%
-839.45
-9.69%
-765.27
+9.26%
-843.39
Net Income From Continuing Operations
-397.91
-11.54%
-356.73
-108.43%
4,231.21
+479.32%
-1,115.46
Depreciation Amortization Depletion
3.35
-76.21%
14.07
-36.15%
22.04
+16.86%
18.86
Depreciation And Amortization
3.35
-76.21%
14.07
-36.15%
22.04
+16.86%
18.86
Other Non Cash Items
57.81
+156.41%
-102.47
-206.70%
96.04
+155.77%
37.55
Stock Based Compensation
346.17
+19.77%
289.03
+44.78%
199.63
-8.34%
217.78
Asset Impairment Charge
15.59
0.00
0.00
—
Operating Gains Losses
-12.00
+97.51%
-481.15
+91.06%
-5,381.18
-18280.86%
-29.28
Gain Loss On Investment Securities
-0.98
—
—
—
Unrealized Gain Loss On Investment Securities
-105.05
-90.35%
-55.19
-215.04%
47.97
+130.47%
20.82
Change In Working Capital
-621.80
-707.05%
-77.05
-504.76%
19.04
+200.00%
6.34
Change In Receivables
-770.24
0.00
0.00
—
Change In Payables And Accrued Expense
147.79
+485.96%
-38.29
-140.42%
94.74
+53.08%
61.89
Change In Accrued Expense
59.33
+689.14%
-10.07
-116.21%
62.13
+8.00%
57.53
Change In Payable
88.46
+413.47%
-28.22
-186.54%
32.61
+648.13%
4.36
Change In Account Payable
3.42
+118.81%
-18.17
-180.09%
22.68
+420.39%
4.36
Change In Other Working Capital
—
—
—
3.30
Change In Other Current Assets
4.04
+111.95%
-33.83
+47.95%
-64.99
-32.40%
-49.09
Change In Other Current Liabilities
-3.39
+31.13%
-4.93
+54.01%
-10.71
-65.96%
-6.46
Investing Cash Flow
-682.33
+61.37%
-1,766.29
-133.94%
5,203.62
+11854.55%
-44.27
Cash Flow From Continuing Investing Activities
-682.33
+61.37%
-1,766.29
-133.94%
5,203.62
+11854.55%
-44.27
Net PPE Purchase And Sale
-8.21
-78.50%
-4.60
-232.78%
-1.38
+89.11%
-12.69
Purchase Of PPE
-8.21
-78.50%
-4.60
-232.78%
-1.38
+89.11%
-12.69
Capital Expenditure
-8.21
-78.50%
-4.60
-232.78%
-1.38
+89.11%
-12.69
Net Investment Purchase And Sale
-667.19
+68.25%
-2,101.52
0.00
0.00
Purchase Of Investment
-4,795.85
-18.08%
-4,061.52
0.00
0.00
Sale Of Investment
4,128.67
+110.65%
1,960.00
0.00
0.00
Net Business Purchase And Sale
-4.42
-101.93%
229.36
+720.18%
-36.98
-134.29%
107.86
Purchase Of Business
-4.42
+85.85%
-31.22
+63.04%
-84.48
-1159.81%
-6.71
Gain Loss On Sale Of Business
-11.03
+97.10%
-379.61
-1058.35%
-32.77
-11.94%
-29.28
Net Other Investing Changes
-2.52
-102.28%
110.47
-97.89%
5,241.99
+3859.48%
-139.43
Financing Cash Flow
134.24
+111.00%
-1,219.79
-390.87%
419.36
-16.04%
499.46
Cash Flow From Continuing Financing Activities
134.24
+111.00%
-1,219.79
-390.87%
419.36
-16.04%
499.46
Net Issuance Payments Of Debt
0.00
+100.00%
-52.75
-71.81%
-30.70
-123.66%
129.75
Issuance Of Debt
—
0.00
0.00
-100.00%
159.90
Repayment Of Debt
0.00
+100.00%
-52.75
-71.81%
-30.70
-1.86%
-30.14
Long Term Debt Issuance
—
0.00
0.00
-100.00%
159.90
Long Term Debt Payments
0.00
+100.00%
-52.75
-71.81%
-30.70
-1.86%
-30.14
Net Long Term Debt Issuance
0.00
+100.00%
-52.75
-71.81%
-30.70
-123.66%
129.75
Net Common Stock Issuance
-125.90
+89.33%
-1,180.45
-369.17%
438.56
+15.50%
379.71
Common Stock Payments
-319.50
+75.29%
-1,293.23
0.00
0.00
Repurchase Of Capital Stock
-319.50
+75.29%
-1,293.23
0.00
0.00
Proceeds From Stock Option Exercised
269.50
+432.36%
50.62
-8.34%
55.23
+1664.50%
3.13
Net Other Financing Charges
-9.37
+74.82%
-37.22
+14.87%
-43.72
-232.91%
-13.13
Changes In Cash
-1,298.45
+66.06%
-3,825.54
-178.75%
4,857.72
+1351.34%
-388.20
Effect Of Exchange Rate Changes
3.77
+404.28%
0.75
+21.27%
0.62
-90.19%
6.28
Beginning Cash Position
2,725.66
-58.39%
6,550.45
+287.12%
1,692.12
-18.41%
2,074.03
End Cash Position
1,430.98
-47.50%
2,725.66
-58.39%
6,550.45
+287.12%
1,692.12
Free Cash Flow
-758.56
+10.13%
-844.05
-10.10%
-766.65
+10.45%
-856.08
Interest Paid Supplemental Data
0.00
-100.00%
5.96
-41.93%
10.27
+93.63%
5.30
Income Tax Paid Supplemental Data
—
61.91
+401.13%
12.35
+140.91%
5.13
Amortization Of Securities
-36.51
+47.81%
-69.96
0.00
0.00
Change In Income Tax Payable
85.05
+945.97%
-10.05
-201.27%
9.93
—
Change In Interest Payable
0.00
0.00
-100.00%
21.98
+18.34%
18.57
Change In Tax Payable
85.05
+945.97%
-10.05
-201.27%
9.93
—
Common Stock Issuance
193.60
+71.66%
112.78
-74.28%
438.56
+15.50%
379.71
Earnings Losses From Equity Investments
—
—
—
—
Issuance Of Capital Stock
193.60
+71.66%
112.78
-74.28%
438.56
+15.50%
379.71
Sale Of Business
0.00
-100.00%
260.59
+448.60%
47.50
-58.54%
114.56
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category